HealthDay News -- Taribavirin (TBV) appears to be a safe and effective alternative to ribavirin (RBV) for treating chronic hepatitis C, with lower associated rates of anemia, according to research published in the October issue of Hepatology.
HealthDay News -- Taribavirin (TBV) appears to be a safe and effective alternative to ribavirin (RBV) for treating chronic hepatitis C, with lower associated rates of anemia, according to research published in the October issue of Hepatology.